Clinical results from the 108-patient randomized controlled leg study
PRINCETON, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI) announces the release of a new randomized controlled clinical trial abstract. As a follow-up to last week's announcement of the clinical results from the 108-patient randomized and controlled leg ulcer study, in which MEDIHONEY became the first advanced wound care dressing proven to accelerate healing in stalled leg ulcers under compression therapy, the results can now be viewed online.
The Active Leptospermum Honey product used in the study, Comvita's WoundCare18+, has since been rebranded to MEDIHONEY.
To view the abstract of the study, please click:
http://www.ncbi.nlm.nih.gov/pubmed/18752540?ordinalpos=2&itool=EntrezSystem2.P
Entrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
(Please copy and paste into your web browser.)
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound-
care products. Its key product, MEDIHONEY, is sold throughout the world by
Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-
based technology -- and is the leading brand of honey-based dressings for the
management of wounds and burns. The product has been shown to be effective in
a variety of wounds and burns, and was recently the focus of a large-scale
randomized controlled trial on leg ulcers. Derma has two products in
development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the
company's novel angiotensin analog for accelerated wound healing and scar
reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007
and is pending its initial FDA marketing clearance. DSC127 was licensed from
The
Contact: Derma Sciences, Inc. Allen & Caron Inc
Edward J. Quilty Rudy Barrio (US Investors)
Chairman and CEO r.barrio@allencaron.com
equilty@dermasciences.com
(609) 514-4744 Brian Kennedy (media)
brian@allencaron.com
(212) 691-8087
SOURCE Derma Sciences, Inc.
International News / Press Release source: PR Newswire
Copyright PR Newswire. All Rights Reserved.